Brave, this new financing is after something big (My view), NTI is in a special situation:
1. Merz european data is plentiful, especially safety.
2. Study of Memantine for neuropathic pain is large, double blind, multicenter and ramdomized. Initially plan for 375 subjects, but final enrollment was 421 subjects.
3. Quality is first rate, executed by Quintiles, the biggest clinical research organization in the world.
4. It was called Phase IIb all along, this is almost a Phase III (or could be extended, and I think they did, to become a phase III).
5. Data could be enough to support an NDA (Ligand did precisely that with their Targretin NDA).
6. This means faster approval, one or two years of time savings, million$ of saving, and a decrease need for dilution, stronger position to negotiate, and still room to developed Xerecept (study was stop short of planned enrollment due to lack of funds).
7, 8, 9, 10. Paul Friedman is a very astute CEO.
11. I did said speculation, but I mentioned a new financing as a possibility.
12. Now the data in December. |
